Suchergebnisse - "Autoimmune Diseases"

PubPharm (17.146)

11

Immunoregulatory natural killer cells

enthalten in: Clinica chimica acta; international journal of clinical chemistry | 2024

von Roe, K.

12

Toosendanin inhibits T-cell proliferation through the P38 MAPK signalling pathway

enthalten in: European journal of pharmacology | 2024

von Zhang, T. | Luo, X. | Jing, L. | +7

13

Glycosylation in autoimmune diseases : A bibliometric and visualization study

enthalten in: Heliyon | 2024

von Deng, G. | Chen, X. | Shao, L. | +2

14

Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM) : A Phase 1 Study Evaluating SC291, a Hypoimmune, Allogeneic CD19-directed CAR T Cell Therapy, in Subjects With Severe Relapsed or Refractory Autoimmune Diseases (GLEAM)

enthalten in: ClinicalTrials.gov | 2024

15

Can we define difficult-to-treat systemic sclerosis?

enthalten in: Expert review of clinical immunology | 2024

von Szűcs, G. | Szekanecz, Z. | Szamosi, S.

16

New insight in treating autoimmune diseases by targeting autophagy

enthalten in: Autoimmunity | 2024

von Lyu, J. | Zhang, H. | Wang, C. | +1

17

Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases : A Multicenter, Open-label, Single-arm, Multiple-dose Study to Characterize the Pharmacokinetics, Safety and Tolerability of Subcutaneous Ianalumab in Chinese Adult Participants With Autoimmune Diseases

enthalten in: ClinicalTrials.gov | 2024

18

Bilateral sudden sensorineural hearing loss in patient with Behçet disease

enthalten in: Ear, nose, & throat journal | 2024

von Chuang, K. | Liu, F. | Chen, H.

19

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) : A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications

enthalten in: ClinicalTrials.gov | 2024

20

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis : A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Basket Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis

enthalten in: ClinicalTrials.gov | 2024